Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Dermatologic 1

Conditions

Sarcoma, Kaposi 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Weight Loss 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Splenomegaly 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioblastoma 1Fever 1Fatigue 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Brain Metastases From Solid Tumors 1Anemia 1Advanced Breast Cancer 1AIDS-related Kaposi sarcoma 1

Interventions

Zidovudine 9Doxorubicin 9Vincristine 6Bleomycin 6Interferon alpha-2 5Etoposide 5tecogalan 4Valganciclovir 4Semaxinib 4Liposomes 4Ritonavir 3Paclitaxel 3Nelfinavir 3Filgrastim 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2liposomal doxorubicin 2interferon alfa-n1 2Indinavir 2Docetaxel 2Didanosine 2Alitretinoin 2vesnarinone 1valspodar 1tocilizumab 1tin etiopurpurin 1pomalidomide 1pembrolizumab 1halofuginone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Sarcoma, Kaposi × Ritonavir × Clear all
NCT00003008 2023-06-15

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Eastern Cooperative Oncology Group

Phase 2 Completed
33 enrolled
Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Sarcoma, Kaposi

NCT00444379 2014-08-20

ARKS

University of California, San Francisco

Phase 4 Completed
224 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

NCT00002366 2009-02-20

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

Abbott

Phase 2 Completed
DermatologicSarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡